Chantix Side Effects can you cope them?
Nausea is one of the side effects listed in the patient information leaflet of Chantix along with other side effects which include changes in dreaming, constipation, gas, and vomiting. But these side effects usually subside after a week of using the medication and quite honestly I have many success stories of individuals that have used Chantix. And I will say that the majority of them did report side effects initially, but the ones that were determined to quit stuck it out and "dealt" with the side effects initially and had a great outcome in the end. It should be noted that most people that I have encountered on Chantix were not bothered enough to stop taking Chantix.
Some have found that most who have failed therapy on Chantix were due to the side effects and as I stated earlier mostly due to the feeling of nausea. However, these same individuals had only tried the medication for two to three days so I also question there true desire to quit smoking.
Thursday, May 29, 2008
Will latest chantix warnings mean new chantix lawsuits?
Aside from the sales impact, the Chantix news could cause another headache for Pfizer: lawsuits.
"These kinds of announcements tend to draw lawyer attention," Funtleyder said. "Some sort of lawsuit is almost inevitable. Whether or not there is any merit is another question."
Pfizer declined to comment on any possible legal issues surrounding a Chantix Lawsuit or any possible sales declines.
The motivation for patients to file liability suits is clear following some huge payouts in recent years. For example, Merck & Co. (MRK) is trying to finalize a $4.85 billion settlement of thousands of suits filed over its painkiller Vioxx, pulled from the market in 2004 because of elevated risk of cardiovascular events.
"It's clear that Chantix is dangerous," said Kristian Rasmussen, a partner with the law firm Cory Watson Crowder & DeGaris in Birmingham, Ala.
Notably, Rasmussen said his firm has received 1,300 inquiries from concerned Chantix users since the release of the report late Wednesday.
But Funtleyder is quick to point out that the Chantix situation is much different than that of Vioxx, and sales are much lower than those of Vioxx, which had $2.5 billion in its last full year.
He doesn't believe the litigation issues will become material, but that the potential legal situation is dynamic and "impossible to handicap."
"These kinds of announcements tend to draw lawyer attention," Funtleyder said. "Some sort of lawsuit is almost inevitable. Whether or not there is any merit is another question."
Pfizer declined to comment on any possible legal issues surrounding a Chantix Lawsuit or any possible sales declines.
The motivation for patients to file liability suits is clear following some huge payouts in recent years. For example, Merck & Co. (MRK) is trying to finalize a $4.85 billion settlement of thousands of suits filed over its painkiller Vioxx, pulled from the market in 2004 because of elevated risk of cardiovascular events.
"It's clear that Chantix is dangerous," said Kristian Rasmussen, a partner with the law firm Cory Watson Crowder & DeGaris in Birmingham, Ala.
Notably, Rasmussen said his firm has received 1,300 inquiries from concerned Chantix users since the release of the report late Wednesday.
But Funtleyder is quick to point out that the Chantix situation is much different than that of Vioxx, and sales are much lower than those of Vioxx, which had $2.5 billion in its last full year.
He doesn't believe the litigation issues will become material, but that the potential legal situation is dynamic and "impossible to handicap."
New Chantix Safety Concerns Rock Pfizer
Could the recent saftey concerns mean more Chantix Lawsuits?
New safety concerns for Pfizer Inc.'s (PFE) smoking- cessation drug could hurt the already stumbling sales acceleration of Chantix and lead to legal trouble for the New York pharmaceutical giant.
A report Wednesday from a watchdog group suggested Chantix may be linked to problems such as heart trouble, seizures and diabetes, adding to the already- known connection to psychiatric problems including suicide and depression. The news adds to the pile of misery in recent years resulting from research and development frustration, a relatively thin pipeline and looming generic competition for its top seller.
"It has been a litany of bad news for Pfizer," said Les Funtleyder, an analyst with Miller Tabak. "This is worse news than we would have supposed, but we weren't exactly positive on (Chantix) anyway."
Pfizer has twice updated the Chantix label for potential side effects since its May 2006 approval. The Food and Drug Administration said in February that it is "increasingly likely" Chantix may be tied to serious psychiatric symptoms.
In late 2006, Pfizer halted development of its highly anticipated cholesterol drug, torcetrapib, and a year later stopped marketing its inhaled insulin product Exubera because of poor demand. Furthermore, its biggest seller, cholesterol drug Lipitor, which brought in more than a quarter of its $11.85 billion in first-quarter revenue, could see generic competition as early as 2010.
New safety concerns for Pfizer Inc.'s (PFE) smoking- cessation drug could hurt the already stumbling sales acceleration of Chantix and lead to legal trouble for the New York pharmaceutical giant.
A report Wednesday from a watchdog group suggested Chantix may be linked to problems such as heart trouble, seizures and diabetes, adding to the already- known connection to psychiatric problems including suicide and depression. The news adds to the pile of misery in recent years resulting from research and development frustration, a relatively thin pipeline and looming generic competition for its top seller.
"It has been a litany of bad news for Pfizer," said Les Funtleyder, an analyst with Miller Tabak. "This is worse news than we would have supposed, but we weren't exactly positive on (Chantix) anyway."
Pfizer has twice updated the Chantix label for potential side effects since its May 2006 approval. The Food and Drug Administration said in February that it is "increasingly likely" Chantix may be tied to serious psychiatric symptoms.
In late 2006, Pfizer halted development of its highly anticipated cholesterol drug, torcetrapib, and a year later stopped marketing its inhaled insulin product Exubera because of poor demand. Furthermore, its biggest seller, cholesterol drug Lipitor, which brought in more than a quarter of its $11.85 billion in first-quarter revenue, could see generic competition as early as 2010.
Subscribe to:
Posts (Atom)